These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2026487)

  • 1. Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
    Von Hoff DD; Green SJ; Neidhart JA; Fabian C; Budd T; Boyd JF; Osborne CK
    Invest New Drugs; 1991 Feb; 9(1):87-8. PubMed ID: 2026487
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase II study of alanosine in advanced large bowel carcinoma.
    Rubin J; Hineman V; Moertel CG; Schutt AJ; Hahn RG
    Am J Clin Oncol; 1983 Apr; 6(2):191-3. PubMed ID: 6829493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.
    Creagan ET; Long HJ; Ahmann DL; Green SJ
    Am J Clin Oncol; 1984 Oct; 7(5):543-4. PubMed ID: 6507375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of acute leukemia with continuous infusion L-Alanosine.
    Weick JK; Tranum BL; Morrison FS
    Invest New Drugs; 1983; 1(3):249-51. PubMed ID: 6678874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of L-alanosine (NSC 15353).
    Goldsmith MA; Ohnuma T; Spigelman M; Greenspan EM; Holland JF
    Cancer; 1983 Feb; 51(3):378-80. PubMed ID: 6821823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial.
    Gockerman JP; Raney M; Logan T
    Cancer Treat Rep; 1985 Sep; 69(9):1029-30. PubMed ID: 3861247
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
    Booth BW; Korzun AH; Weiss RB; Ellison RR; Budman D; Khojasteh A; Wood W
    Cancer Treat Rep; 1986 Oct; 70(10):1247-8. PubMed ID: 3530455
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I study of L-alanosine using a daily x 3 schedule.
    Dosik GM; Stewart D; Valdivieso M; Burgess MA; Bodey GP
    Cancer Treat Rep; 1982 Jan; 66(1):73-6. PubMed ID: 7053269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of aclacinomycin-A (NSC-208734) in adenocarcinoma of the kidney.
    Decker DA; Drelichman A; Opipari MI; Al-Sarraf M
    Am J Clin Oncol; 1984 Oct; 7(5):527-8. PubMed ID: 6594927
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II clinical trial of acivicin in advanced breast cancer: an Eastern Cooperative Oncology Group Study.
    Willson JK; Knuiman MW; Skeel RT; Wolter JM; Pandya KJ; Falkson G; Chang YC
    Cancer Treat Rep; 1986 Oct; 70(10):1237-8. PubMed ID: 3530452
    [No Abstract]   [Full Text] [Related]  

  • 11. Alanosine (UCSD).
    Yu J
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1623-30. PubMed ID: 11763167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
    Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
    Vaughn CB; Panettiere F; Thigpen T; Bottomley R; Hoogstraten B; Samal B
    Cancer Treat Rep; 1981; 65(5-6):443-5. PubMed ID: 7237465
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma.
    Carroll DS; Kemeny NE; Gralla RJ
    Cancer Treat Rep; 1979 Jan; 63(1):139-40. PubMed ID: 369686
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
    Wander HE; Meyer D; Schuff-Werner P; Nagel GA
    Onkologie; 1986 Aug; 9(4):236-8. PubMed ID: 3531951
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Nichols WC; Kvols LK; Ingle JN; Edmonson JH; Ahmann DL; Rubin J; O'Connell MJ
    Cancer Treat Rep; 1978 May; 62(5):837-9. PubMed ID: 657166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET; O'Connell MJ; Kovach JS
    Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of 4'-epi-doxorubicin in advanced breast cancer.
    Campora E; Nobile MT; Sertoli MR; Rosso R
    Cancer Treat Rep; 1984 Oct; 68(10):1285-6. PubMed ID: 6597003
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
    Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
    Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
    [No Abstract]   [Full Text] [Related]  

  • 20. A clinical trial of mithramycin in the treatment of advanced malignant disease.
    Baum M
    Br J Cancer; 1968 Jun; 22(2):176-83. PubMed ID: 4873186
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.